Parallax Volatility Advisers, L.P. Editas Medicine, Inc. Transaction History

Parallax Volatility Advisers, L.P.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $21,901 - $29,466	-3,165 Reduced 63.17%	1,845 $14,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $12,312 - $22,205	1,936 Added 62.98%	5,010 $41,000
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $4,225 - $6,929	-601 Reduced 16.35%	3,074 $22,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $778,993 - $1.24 Million	-93,629 Reduced 96.22%	3,675 $32,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $114,486 - $182,839	9,415 Added 10.71%	97,304 $1.19 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $240,978 - $515,004	24,122 Added 37.83%	87,889 $1.04 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $633,374 - $1.24 Million	-44,984 Reduced 41.36%	63,767 $1.21 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $2.05 Million - $3.14 Million	77,313 Added 245.92%	108,751 $2.89 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $752,138 - $1.4 Million	-19,153 Reduced 37.86%	31,438 $1.29 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $1.17 Million - $2.12 Million	37,440 Added 284.69%	50,591 $2.87 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $522,226 - $1.19 Million	13,151 New	13,151 $552,000
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $8,709 - $12,092	-315 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $9,891 - $12,918	315 New	315 $11,000
Q1 2018 May 15, 2018	SELL	$29.84 - $44.08 $154,153 - $227,717	-5,166 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $113,083 - $161,902	5,166	5,166 $159,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.